Treosulfan

Generic Name: Treosulfan

Brand Names: Trecondi

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₄O_₈S_₂

CAS Number: 299-75-2

Unique Ingredient Identifier: CO61ER3EPI

Background: Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.

Indication: Not Available

Associated Conditions: -

Associated Therapies: HSCT conditioning therapy

Clinical Trials

Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases

Phase 2

Completed

Conditions: Haemoglobinopathies
Primary Immunodeficiencies
Bone Marrow Failure Syndromes
Inborn Errors of Metabolism

Interventions: Drug: Treosulfan
Drug: Busilvex

First Posted Date: 2015-01-29

Last Posted Date: 2023-11-03

Lead Sponsor: medac GmbH

Target Recruit Count: 106

Registration Number: NCT02349906

Locations: 🇩🇪
University Hospital Frankfurt, Frankfurt am Main, Germany
🇮🇹
S.C. Oncoematologia Pediatrica Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
🇮🇹
Oncoematologia Pediatrica A.O. di Perugia Ospedale S. Maria della Misericordia, Perugia, Italy

and more 18 locations

Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies

Phase 2

Completed

Conditions: Myelodysplastic Syndromes (MDS)
Acute Lymphoblastic Leukaemias (ALL)
Acute Myeloid Leukaemias (AML)
Juvenile Myelomonocytic Leukaemias (JMML)

Interventions: Drug: Treosulfan

First Posted Date: 2015-01-07

Last Posted Date: 2020-05-04

Lead Sponsor: medac GmbH

Target Recruit Count: 70

Registration Number: NCT02333058

Locations: 🇩🇪
Medical University Hannover, Hannover, Germany
🇩🇪
University Clinic Hamburg-Eppendorf, Hamburg, Germany
🇬🇧
Birmingham Children's Hospital, Birmingham, United Kingdom

and more 21 locations

Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT

Completed

Conditions: Allogeneic Haematopoietic Stem Cell Transplantation

Interventions: Drug: Treosulfan

First Posted Date: 2014-01-29

Last Posted Date: 2019-09-04

Lead Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust

Target Recruit Count: 61

Registration Number: NCT02048800

Locations: 🇬🇧
Great North Childrens Hospital, Newcastle Upon Tyne, United Kingdom
🇬🇧
Great Ormond Street Hospital for Children, London, United Kingdom

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukaemia

Interventions: Drug: VP16
Drug: Thiotepa
Radiation: TBI
Drug: Treosulfan
Drug: Fludarabine
Drug: Busulfan
Drug: ATG Thymoglobulin
Drug: Grafalon
Drug: Cyclophosphamide

First Posted Date: 2013-09-24

Last Posted Date: 2024-01-16

Lead Sponsor: St. Anna Kinderkrebsforschung

Target Recruit Count: 1800

Registration Number: NCT01949129

Locations: 🇦🇷
Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit, La Plata, Argentina
🇧🇪
University Hospitals Leuven Kinderhemato-oncologie, Leuven, Belgium
🇮🇱
Dana Children's Hospital, Tel Aviv, Israel

and more 115 locations

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 2

Conditions: Acute Myeloid Leukemia in Remission
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Minimal Residual Disease
Myelodysplastic/Myeloproliferative Neoplasm
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Fludarabine Phosphate
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Treosulfan
Radiation: Total-Body Irradiation
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-07-10

Last Posted Date: 2021-06-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 102

Registration Number: NCT01894477

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

T&B Depletion Non Malignant

Phase 2

Conditions: Graft Versus Host Disease

Interventions: Biological: polyclonal antibody
Drug: Treosulfan
Drug: Rituximab
Drug: Fludarabine
Drug: Thiotepa
Drug: Cyclosporine A
Drug: Methotrexate

First Posted Date: 2013-03-14

Last Posted Date: 2013-03-14

Lead Sponsor: Franco Locatelli

Target Recruit Count: 130

Registration Number: NCT01810926

Locations: 🇮🇹
San Raffaele Scientific Institute, Milano, Italy
🇮🇹
University of Cagliari, Cagliari, Italy
🇮🇹
University of Milano-Bicocca San Gerardo Hospital, Monza, Italy

and more 1 locations

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)

Interventions: Drug: Treosulfan

First Posted Date: 2013-01-21

Last Posted Date: 2016-10-12

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 40

Registration Number: NCT01772953

Locations: 🇺🇸
Washington University, St. Louis Children's, St. Louis, Missouri, United States
🇺🇸
Children's National Medical Center, Washington, DC, District of Columbia, United States
🇺🇸
Children's Hospital of Alabama/UAB, Birmingham, Alabama, United States

and more 20 locations

Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

Phase 2

Conditions: Hodgkin Lymphoma
Non Hodgkin Lymphoma

Interventions: Drug: treosulfan

First Posted Date: 2010-03-02

Last Posted Date: 2016-04-20

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 40

Registration Number: NCT01079013

Locations: 🇮🇱
Chaim Sheba Medical Center, Tel-Hashomer, Israel

Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)

Phase 2

Completed

Conditions: Acute Myeloid Leukaemia

Interventions: Drug: Treosulfan

First Posted Date: 2010-02-05

Last Posted Date: 2010-02-05

Lead Sponsor: medac GmbH

Target Recruit Count: 75

Registration Number: NCT01063660

Locations: 🇩🇪
University of Rostock, Rostock, Germany

Dose-range Finding Treosulfan-based Conditioning

Phase 1

Completed

Conditions: Hematological Malignancies

Interventions: Drug: Treosulfan

First Posted Date: 2010-02-05

Last Posted Date: 2023-11-03

Lead Sponsor: medac GmbH

Target Recruit Count: 56

Registration Number: NCT01063647

Locations: 🇵🇱
Silesian Medical University, Katowice, Poland
🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇩🇪
Charité University Hospital Berlin, Berlin, Germany

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy